Novel antifungal drug shows promise in some patients with Valley Fever
Novel antifungal drug shows promise in some patients with Valley Fever. A subanalysis of a single-group, open-label, Phase IIb study found that olorofim, a first-in-class orotomide antifungal agent that does not have U.S.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: A subanalysis of a single-group, open-label, Phase IIb study found that olorofim, a first-in-class orotomide antifungal agent that does not have U.S. FDA approval, showed efficacy in patients with disseminated coccidioidomycosis (DCM), a rare complication of Valley Fever in which the fungus spreads from the lungs to other parts of the body.
- Ponto de atenção: novel.
- Ponto de atenção: antifungal.
- Ponto de atenção: drug.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.
